Crossmark

The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity

Crossref DOI link: https://doi.org/10.1186/s12964-025-02129-8

Published Online: 2025-06-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hmedat, Ali N. A.

Doondeea, Jessica

Ebner, Daniel

Feller, Stephan M.

Lewitzky, Marc
Funding

Funding for this research was provided by:

Yarmouk University, Irbid, Jordan

Wilhelm-Sander-Stiftung Munich (2015.102.1)

HeadsUp, Oxford, UK
License Information

Text and Data Mining valid from 2025-06-19

Version of Record valid from 2025-06-19
More Information

Article History

Received: 22 October 2024

Accepted: 25 February 2025

First Online: 19 June 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below